Mason Street Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-11,384
| Closed | -$107K | – | 1527 |
|
|
2020
Q3 | $107K | Sell |
11,384
-1,483
| -12% | -$14.1K | ﹤0.01% | 1450 |
|
|
2020
Q2 | $98K | Buy |
12,867
+1,054
| +9% | +$8.06K | ﹤0.01% | 1455 |
|
|
2020
Q1 | $73K | Hold |
11,813
| – | – | ﹤0.01% | 1457 |
|
|
2019
Q4 | $144K | Buy |
11,813
+302
| +3% | +$3.3K | ﹤0.01% | 1447 |
|
|
2019
Q3 | $133K | Buy |
11,511
+240
| +2% | +$2.53K | ﹤0.01% | 1435 |
|
|
2019
Q2 | $113K | Buy |
11,271
+123
| +1% | +$1.33K | ﹤0.01% | 1453 |
|
|
2019
Q1 | $144K | Buy |
11,148
+423
| +4% | +$6.3K | ﹤0.01% | 1472 |
|
|
2018
Q4 | $163K | Buy |
10,725
+511
| +5% | +$9.74K | ﹤0.01% | 1377 |
|
|
2018
Q3 | $204K | Buy |
10,214
+301
| +3% | +$6.85K | ﹤0.01% | 1366 |
|
|
2018
Q2 | $193K | Buy |
9,913
+456
| +5% | +$10.1K | ﹤0.01% | 1385 |
|
|
2018
Q1 | $191K | Buy |
9,457
+257
| +3% | +$4.35K | ﹤0.01% | 1351 |
|
|
2017
Q4 | $122K | Buy |
9,200
+263
| +3% | +$3.97K | ﹤0.01% | 1435 |
|
|
2017
Q3 | $165K | Buy |
8,937
+295
| +3% | +$5.5K | ﹤0.01% | 1362 |
|
|
2017
Q2 | $159K | Buy |
8,642
+612
| +8% | +$12.1K | ﹤0.01% | 1354 |
|
|
2017
Q1 | $181K | Buy |
8,030
+554
| +7% | +$13.3K | ﹤0.01% | 1304 |
|
|
2016
Q4 | $260K | Buy |
7,476
+445
| +6% | +$13.3K | 0.01% | 1162 |
|
|
2016
Q3 | $172K | Buy |
7,031
+271
| +4% | +$6.77K | ﹤0.01% | 1259 |
|
|
2016
Q2 | $162K | Buy |
6,760
+583
| +9% | +$13.4K | ﹤0.01% | 1241 |
|
|
2016
Q1 | $145K | Buy |
+6,177
| New | +$147K | ﹤0.01% | 1242 |
|
Mason Street Advisors's AMAG Position: Q4 2020 in Review
Mason Street Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 11,384 shares — an estimated $107K sold.
Mason Street Advisors first reported a position in AMAG in Q1 2016 and held it in 19 quarters. The position peaked at $260K in Q4 2016. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Mason Street Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Mason Street Advisors sold 11,384 AMAG Pharmaceuticals shares in Q4 2020, an estimated $107K.
- Mason Street Advisors first reported a position in AMAG Pharmaceuticals in Q1 2016 and held it in 19 quarters.
- Mason Street Advisors's AMAG Pharmaceuticals position peaked at $260K in Q4 2016.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Mason Street Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.